Loading news...
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were incorrect.
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on January 23, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 12 new employees in restricted stock units for an aggregate of 34,199 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
Harvey Capital Management Inc. lessened its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 16.8% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,830 shares of the company's stock after selling 8,655 shares during the period. Harvey Capital Management Inc.'s
Emerald Advisers LLC lessened its stake in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 29.5% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 720,343 shares of the company's stock after selling 300,914 shares during the quarter. BridgeBio Pharma accounts for
PALO ALTO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a new type of biopharmaceutical company focused on genetic diseases, announced today the pricing of $550 million aggregate principal amount of 0.75% convertible senior notes due 2033 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional $82.5 million aggregate principal amount of notes. The sale of the notes is expected to close on January 21, 2026, subject to customary closing conditions.
-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
- Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript
PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12 at 7:30 am PT.
PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET with Janet Legare, M.D., Professor in the Divisions of Genetics and Metabolism and Developmental Pediatrics and Rehabilitation Medicine in the Department of Pediatrics at the University of Wisconsin (UW) School of Medicine and Public Health and investigator in PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia. Dr. Legare also serves as director of both the Midwest Regional Bone Dysplasia Clinic and the Neuromotor Development Clinic, both affiliated with UW Health Kids.
BridgeBio had a very successful 2025 with a strong commercial launch of Attruby and successful phase 3 readouts of BBP-418 and infigratinib. I expect 2026 to be another strong year with Attruby U.S. net sales in the $900-950 million range and I expect BridgeBio will reach non-GAAP profitability in Q4 2026. Infigratinib's phase 3 results are expected in the following weeks and represent the next important catalyst for the company.
PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on December 18, 2025, the compensation committee of BridgeBio's board of directors approved equity grants to 9 new employees in restricted stock units for an aggregate of 29,472 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.
Shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twenty-two ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and twenty-one have issued a buy rating on the company. The average 12-month
Assenagon Asset Management S.A. decreased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 26.1% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 258,904 shares of the company's stock after selling 91,507 shares during the period. Assenagon Asset Management S.A. owned
BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) CEO Neil Kumar sold 30,011 shares of BridgeBio Pharma stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $74.64, for a total transaction of $2,240,021.04. Following the transaction, the chief executive officer directly owned 228,776 shares of
Frontier Capital Management Co. LLC lowered its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 30.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 535,763 shares of the company's stock after selling 233,538 shares during the period. Frontier Capital
Pre-Market Stock Futures: Futures are trading lower after a big rate-cut rally on Wednesday was sideswiped by Oracle's disappointing earnings after the bell yesterday. The Federal Reserve's 25-basis-point rate cut, as expected, put the benchmark rate at 3.50%-3.75%. The third consecutive cut lowered rates to their lowest level since late 2022, to help support a... Here Are Thursday's Top Wall Street Analyst Research Calls: American Eagle Outfitters, Ferrari, Intuitive Surgical, Roku, PayPal, Synopsis, Visa, and More.
Federated Hermes Inc. bought a new position in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 277,587 shares of the company's stock, valued at approximately $11,986,000. Federated Hermes Inc. owned about
Edgestream Partners L.P. purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 44,556 shares of the company's stock, valued at approximately $1,924,000. A number of other large investors